Life Biosciences, based in Boston, develops cellular rejuvenation therapies using partial epigenetic reprogramming, led by ER-100 for optic neuropathies. It announced an $80 million Series D in April 2026 and dosed the first patient in its ER-100 trial in June 2026.
At a glance
| Price from | Custom |
| Best for | Partners in eye disease and reprogramming |
From Life Biosciences's own website.
What stands out
- First reprogramming therapy in humans
- Clear initial indication
Worth knowing
- Phase 1 stage
- Narrow first target in eye disease
How it ranks
Life Biosciences is ranked 6th of 10 in Best Longevity Startups (Lister Score 90.4).
#6 in Best Longevity Startups · Lister Score 90.4
The FDA cleared Life Biosciences' IND for ER-100 in January 2026, which the company calls the first partial epigenetic reprogramming therapy to reach human trials..
| Rank | Best Longevity Startups | Score |
|---|---|---|
| 1 | Altos Labs | 96.8 |
| 2 | NewLimit | 95.6 |
| 3 | Retro Biosciences | 94.3 |
| 4 | Loyal | 93.1 |
| 5 | Function Health | 91.8 |
| 6 | Life Biosciences | 90.4 |
| 7 | Juvenescence | 89.1 |
| 8 | Rubedo Life Sciences | 87.7 |
| 9 | Cambrian Bio | 86.4 |
| 10 | Gameto | 85.0 |
Frequently asked questions
How does Life Biosciences rank on Lister?
Life Biosciences is ranked 6th of 10 in Best Longevity Startups (Lister Score 90.4).
Appears in
Add this badge to your site
If you work at Life Biosciences, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.